A total of 16 viral vector-based universal influenza vaccines are in preclinical studies, and these vaccines have a more diverse selection of targets, including HA, NA, NP, M1, and PB1, combined with immunofocusing or T-cell strategies based on multi-targeted combination strategy design. This evidence concerns the gene XK and influenza.